AllSci News
MoonLake's sonelokimab sustains deep responses in Phase III hidradenitis suppurativa trials at week 40
MoonLake Immunotherapeutics (Nasdaq: MLTX) reported Week 40 data from its Phase III VELA program evaluating sonelokimab in hidradenitis suppurativa, showing...
Otsuka Expands Psychiatric Portfolio With USD 1.225b Acquisition of Transcend Therapeutics
Otsuka Pharmaceutical Co., Ltd. has entered into an agreement to fully acquire Transcend Therapeutics, Inc., a clinical-stage biotechnology company...
OKYO Pharma raises USD 20m in underwritten public offering
UK-based OKYO Pharma Limited (Nasdaq: OKYO) announced the pricing of an underwritten public offering of ordinary shares for gross proceeds of approximately...
FDA Approves Wellcovorin by GSK as First Treatment for Cerebral Folate Transport Deficiency
The US FDA approved Wellcovorin (leucovorin calcium) tablets on March 10, 2026, for the treatment of cerebral folate deficiency in adult and pediatric...
Akeso advances AK146D1 and AK138D1 into phase II trials for advanced solid tumors
Akeso, Inc. (Hong Kong; HKEX: 9926.HK) announced on March 24, 2026, that it has received clearance from China's National Medical Products Administration to...
Theriva Biologics out-licenses SYN-020 to Rasayana Therapeutics in USD 38.3m worldwide deal
Theriva Biologics (NYSE American: TOVX), a clinical-stage company headquartered in Rockville, Maryland, announced an exclusive worldwide SYN-020 license...
Lyell Immunopharma raises USD 50m in additional equity private placement tranche
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage cell therapy company based in South San Francisco, California, announced the closing of an...
Rapport Therapeutics licenses RAP-219 to Tenacia Biotechnology in USD 328m. Greater China deal
Rapport Therapeutics Licenses RAP-219 to Tenacia Biotechnology for Greater China Development and Commercialization
Abbisko Therapeutics Launches Phase I/II Trial of ABSK141 KRAS G12D Inhibitor in Solid Tumors
For decades, the KRAS G12D mutation sat at the top of oncology's most-wanted list — prevalent, lethal, and stubbornly resistant to pharmacological...
Tetragon Biosciences Launches Phase 1 Trial of TET2 Agonist GLIX1 in Recurrent Glioblastoma
Tetragon Biosciences has opened a Phase 1 clinical trial of GLIX1, an oral small molecule that agonizes TET2, in adults with recurrent or progressive...
Acumen Pharmaceuticals raises USD 35.75m in private placement
Acumen Pharmaceuticals (Nasdaq: ABOS), a U.S.-based clinical-stage biopharmaceutical company, announced a private placement of approximately USD 35.75...
Aardvark Therapeutics pauses ARD-101 Prader-Willi syndrome trials after cardiac safety signal emerges
Aardvark Therapeutics has voluntarily paused enrollment and dosing in its Phase III HERO trial and open-label extension study evaluating ARD-101 for the...
Azenta and Frontier Space Partner on $X Million Space Life Sciences Research Mission
Burlington, MA and London, UK - Azenta Life Sciences (Nasdaq: AZTA) and Frontier Space have announced a groundbreaking strategic partnership aimed at...
FDA accepts Sun Pharma's Ilumya application for active psoriatic arthritis in adults
Sun Pharmaceutical Industries has submitted a supplemental Biologics License Application to the US FDA seeking approval for ILUMYA (tildrakizumab-asmn) for...
Argo Biopharma Secures FDA Fast Track Designation for siRNA Therapy BW-20805 Targeting Hereditary Angioedema
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company headquartered in Shanghai and New York, announced that the U.S....
The AllSci Brief
Systematic R&D and deal news. Daily.